Gabriella Girelli

Gabriella Girelli

Auto-generated profile, based on publicly available information

Gabriella Girelli

Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2000 in Blood
Verified
Journal Article
Open access
Francesca Romana MauroFrancesca Romana Mauro
Francesca Romana Mauro
RFRobert Foa
Robert Foa
RCRaffaella Cerretti
Raffaella Cerretti
DGDiana Giannarelli
Diana Giannarelli
SCSerelina Coluzzi
Serelina Coluzzi
GGGabriella Girelli
Gabriella Girelli
Fifty-two cases of autoimmune hemolytic anemia (AHA) were observed within a series of 1203 patients (4.3%) with chronic lymphocytic leukemia (CLL) followed at a single institution. Nineteen were observed at the time of CLL diagnosis and 33 during the clinical follow-up. Ninety percent of the patients with CLL/AHA showed active CLL and 25% had been treated previously. The antierythrocyte autoantibody (AeAb) was an IgG in 87% of cases and an IgM in 13%. A lymphocyte count more than 60 × 109/L (P < .00001), age above 65 years (P < .01), and male gender (P < .01) emerged as independent parameters that correlated significantly with an increased rate of AHA at CLL diagnosis. Patients previously treated with chlorambucil (CB) plus prednisone (PDN) and with fludarabine plus PDN showed a similar rate of AHA (1.8% and 2.5%, respectively). After steroid therapy associated with CB in case of active CLL, 70% of patients achieved the complete disappearance of the AeAb. The actuarial AHA relapse-free survival probability was 54% at 5 years and the median survival probability after AHA was 41 months. Infections represented the main cause of morbidity and mortality. IgG AHA and the occurrence of AHA at the same time of CLL diagnosis emerged as independent factors significantly correlated with a better survival probability of AHA/CLL patients. Taken together, this study indicates that in CLL, AHA is a rare event with no independent effect on survival for which steroids, associated with CB if required, and a careful management of infections may successfully control the 2 conditions. Cooperative studies are needed to better define the optimal steroid schedule and the therapeutic role of other immunosuppressive agents and splenectomy.

9 January 2014 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
LCLuciana Chessa
Luciana Chessa
VLVincenzo Leuzzi
Vincenzo Leuzzi
APAlessandro Plebani
Alessandro Plebani
ASAnnarosa Soresina
Annarosa Soresina
RMRoberto Micheli
Roberto Micheli
Mauro MagnaniMauro Magnani
Mauro Magnani
Background: Ataxia Teleangiectasia [AT] is a rare neurodegenerative disease characterized by early onset ataxia, oculocutaneous teleangiectasias, immunodeficiency, recurrent infections, radiosensitivity and proneness to cancer. No therapies are available for this devastating disease. Recent observational studies in few patients showed beneficial effects of short term treatment with betamethasone. To avoid the characteristic side effects of long-term administration of steroids we developed a method for encapsulation of dexamethasone sodium phosphate (DSP) into autologous erythrocytes (EryDex) allowing slow release of dexamethasone for up to one month after dosing. Aims of the study were: the assessment of the effect of EryDex in improving neurological symptoms and adaptive behaviour of AT patients; the safety and tolerability of the therapy.Methods: Twenty two patients (F:M = 1; mean age 11.2 ± 3.5) with a confirmed diagnosis of AT and a preserved or partially supported gait were enrolled for the study. The subjects underwent for six months a monthly infusion of EryDex. Ataxia was assessed by the International Cooperative Ataxia Rating Scale (ICARS) and the adaptive behavior by Vineland Adaptive Behavior Scales (VABS). Clinical evaluations were performed at baseline and 1, 3, and 6 months.Results: An improvement in ICARS (reduction of the score) was detected in the intention-to-treat (ITT) population (n = 22; p = 0.02) as well as in patients completing the study (per protocol PP) (n = 18; p = 0.01), with a mean reduction of 4 points (ITT) or 5.2 points (PP). When compared to baseline, a significant improvement were also found in VABS (increase of the score) (p < 0.0001, ITT, RMANOVA), with statistically significant increases at 3 and 6 months (p < 0.0001). A large inter-patient variability in the incorporation of DSP into erythrocytes was observed, with an evident positive effect of higher infusion dose on ICARS score decline. Moreover a more marked improvement was found in less neurologically impaired patients. Finally, a 19 month-extension study involving a subgroup of patients suggested that Erydex treatment can possibly delay the natural progression of the disease.EryDex was well tolerated; the most frequent side effects were common AT pathologies.Conclusions: EryDex treatment led to a significant improvement in neurological symptoms, without association with the typical steroid side effects.Trial registration: Current Controlled Trial2010-022315-19SpA

1 March 2000 in Transfusion
Verified
Journal Article
Closed access
PDF file
IMIrene Messana
Irene Messana
LFL. Ferroni
L. Ferroni
Francesco MisitiFrancesco Misiti
Francesco Misiti
GGG. Girelli
G. Girelli
SPS. Pupella
S. Pupella
BGB. Giardina
B. Giardina

11 October 2004 in Gut
Verified
Journal Article
Open access
PDF file
ESE Spada
E Spada
AMA Mele
A Mele
ABA Berton
A Berton
LRL Ruggeri
L Ruggeri
LFL Ferrigno
L Ferrigno
AFA Folgori
A Folgori
Background/Aims: Hepatitis C virus (HCV) infection results in a high frequency of chronic disease. The aim of this study was to identify early prognostic markers of disease resolution by performing a comprehensive analysis of viral and host factors during the natural course of acute HCV infection. Methods: The clinical course of acute hepatitis C was determined in 34 consecutive patients. Epidemiological and virological parameters, as well as cell mediated immunity (CMI) and distribution of human leukocyte antigens (HLA) alleles were analysed. Results: Ten out of 34 patients experienced self-limiting infection, with most resolving patients showing fast kinetics of viral clearance: at least one negative HCV RNA test during this phase predicted a favourable outcome. Among other clinical epidemiological parameters measured, the self-limiting course was significantly associated with higher median peak bilirubin levels at the onset of disease, and with the female sex, but only the latter parameter was independently associated after multivariate analysis. No significant differences between self-limiting or chronic course were observed for the distribution of DRB1 and DQB1 alleles. HCV specific T cell response was more frequently detected during acute HCV infection, than in patients with chronic HCV disease. A significantly broader T cell response was found in patients with self-limiting infection than in those with chronic evolving acute hepatitis C. Conclusion: The results suggest that host related factors, in particular sex and CMI, play a crucial role in the spontaneous clearance of this virus. Most importantly, a negative HCV RNA test and broad CMI within the first month after onset of the symptoms represent very efficacious predictors of viral clearance and could thus be used as criteria in selecting candidates for early antiviral treatment.

20 December 2006 in Transfusion
Verified
Journal Article
Closed access
PDF file
SVStefania Vaglio
Stefania Vaglio
MAMaria Cristina Arista
Maria Cristina Arista
MPMaria Paola Perrone
Maria Paola Perrone
GTGabriella Tomei
Gabriella Tomei
ATAnna Maria Testi
Anna Maria Testi
GGGabriella Girelli
Gabriella Girelli

1 April 2000 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
CGC. Garufi
C. Garufi
SVS. Vaglio
S. Vaglio
SBS. Brienza
S. Brienza
LCL. Conti
L. Conti
RDR. M. D'Attino
R. M. D'Attino
ETE. Terzoli
E. Terzoli
C. Garufi, S. Vaglio, S. Brienza, L. Conti, R. M. D'Attino, G. Girelli, E. Terzoli; Immunohemolytic anemia following oxaliplatin administration, Annals of Onco